The FDA granted accelerated approval to Bristol Myers Squibb’s iberdomide (marketed as Zenbexus) for multiple myeloma patients whose disease has returned or stopped responding to treatment, the company confirmed. The approval adds another oral option in the expanding multiple myeloma landscape and underscores the regulator’s continued use of accelerated pathways in oncology. With iberdomide entering the clinic for relapsed/refractory myeloma under accelerated approval, companies will now focus on confirmatory evidence and real-world uptake—particularly as competitors broaden combinations across lines of therapy. The decision also highlights how oral, targeted mechanisms are increasingly shaping treatment sequencing.